Ethylvanillin demonstrates a range of bioactivities and therapeutic potentials. It exhibits antitubercular activity against Mycobacterium tuberculosis H37Rv, albeit with a relatively low potency, reflected by a Minimum Inhibitory Concentration (MIC) value greater than 400,000 nM. The compound shows varying degrees of potency in several assays: 25,118.9 nM in inhibiting Aldehyde Dehydrogenase 1 (ALDH1A1), 7,943.3 nM in the Cell Viability assay, 7,079.5 nM as a small molecule agonist of retinoid X receptor alpha signaling, and 50,118.7 nM as an antagonist of peroxisome proliferator-activated receptor delta signaling. It also inhibits the growth of various human tumor cell lines with specific GI50 values such as 100,000.0 nM in several cancer cell lines, and lower GI50 values in SR Leukemia (76,032.63 nM) and SNB-75 CNS cell lines (95,060.48 nM). Additionally, it acts as an agonist in the antioxidant response element (ARE) signaling pathway with a potency of 74,978.0 nM.
In the context of envenomation, Ethylvanillin provides protection against venom-induced mortality and hemorrhage from Daboia russellii and Naja kaouthia in Swiss albino mice. This efficacy is observed both before and after venom administration, showcasing its potential as an antivenom agent. The compound has a lipophilicity value of 1.81, indicating decent solubility in lipids.
For viral infections, Ethylvanillin exhibits modest antiviral activity against SARS-CoV-2. It inhibits SARS-CoV-2-induced cytotoxicity in Caco-2 and Vero-6 cells at a 10 μM concentration, with inhibition rates of -2.44% and -0.06% respectively, after 48-hour exposures. Furthermore, it shows 8.127% inhibition of the SARS-CoV-2 3CL-Pro protease at a 20 μM concentration.
Lastly, Ethylvanillin exhibits inhibitory activity in HDAC6 enzymatic assays, with -10.64% inhibition using a commercial peptide substrate and -3.93% inhibition using a custom peptide substrate, hinting at potential roles in modulating epigenetic targets..
Note: Summary generated by AI. Data source: ChEMBL 